| scholarly article | Q13442814 |
| P50 | author | Albert Pares | Q40418471 |
| Susanna Coll | Q54505092 | ||
| P2093 | author name string | Rodés J | |
| Moreno J | |||
| Ortiz P | |||
| Caballero A | |||
| García-Buey L | |||
| Moreno-Otero R | |||
| Caballería J | |||
| Benita V | |||
| Mato JM | |||
| Solà R | |||
| Beltrán J | |||
| Puerta JL | |||
| Boissard G | |||
| Martín-Duce A | |||
| Correa JA | |||
| Barrao F | |||
| Caballería L | |||
| García-Magaz I | |||
| Cámara J | |||
| Barrao E | |||
| Fernández de Paz J | |||
| P2860 | cites work | S-adenosylmethionine synthesis: molecular mechanisms and clinical implications | Q28646532 |
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease | Q34544061 | ||
| Expression of rat liver S-adenosylmethionine synthetase in Escherichia coli results in two active oligomeric forms | Q42041181 | ||
| Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis | Q42552980 | ||
| Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury | Q42988063 | ||
| The Alcohol-altered Liver Membrane Antibody and Hepatitis C Virus Infection in the Progression of Alcoholic Liver Disease | Q43038521 | ||
| Inhibition by ethanol of rat liver plasma membrane (Na+,K+)ATPase: protective effect of S-adenosyl-L-methionine, L-methionine, and N-acetylcysteine | Q44630979 | ||
| Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis | Q47176613 | ||
| Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products | Q48777148 | ||
| Defective methionine metabolism in cirrhosis: relation to severity of liver disease. | Q51605191 | ||
| Labile methyl balances for normal humans on various dietary regimens | Q66925044 | ||
| Protective role of S-adenosyl-l-methionine against acetaminophen induced mortality and hepatotoxicity in mice | Q66989967 | ||
| Protective role of S-adenosyl-L-methionine on liver injury induced by D-galactosamine in rats | Q67389108 | ||
| S-adenosylmethionine treatment prevents carbon tetrachloride-induced S-adenosylmethionine synthetase inactivation and attenuates liver injury | Q67555817 | ||
| S-adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models | Q67743365 | ||
| Is colchicine effective therapy for cirrhosis? | Q68141125 | ||
| S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis | Q68257612 | ||
| Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study | Q68512879 | ||
| S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon | Q68716606 | ||
| Effect of S-adenosyl-L-methionine on thioacetamide-induced liver damage in rats | Q69581218 | ||
| Effect of the variations of S-adenosyl-L-methionine liver content on fat accumulation and ethanol metabolism in ethanol-intoxicated rats | Q69991963 | ||
| Purification and comparison of two forms of S-adenosyl-L-methionine synthetase from rat liver | Q70369978 | ||
| Hypermethioninemia associated with methionine adenosyltransferase deficiency: Clinical, morphologic, and biochemical observations on four patients | Q70766918 | ||
| Evidence that S-adenosylmethionine and N-acetylcysteine reduce injury from sequential cold and warm ischemia in the isolated perfused rat liver | Q72409789 | ||
| Treatment of alcoholic liver disease | Q72847017 | ||
| S-adenosyl-L-methionine protects the liver against the cholestatic, cytotoxic, and vasoactive effects of leukotriene D4: a study with isolated and perfused rat liver | Q73574973 | ||
| Interaction of liver methionine adenosyltransferase with hydroxyl radical | Q73804234 | ||
| Rate of Disappearance From Plasma of Intravenously Administered Methionine in Patients With Liver Damage | Q81148006 | ||
| S-adenosyl-L-methionine protection against alpha-naphthylisothiocyanate-induced cholestasis in the rat | Q93678999 | ||
| P433 | issue | 6 | |
| P921 | main subject | liver cirrhosis | Q147778 |
| multicenter clinical trial | Q6934595 | ||
| placebo | Q269829 | ||
| alcoholic liver cirrhosis | Q6470994 | ||
| P304 | page(s) | 1081-1089 | |
| P577 | publication date | 1999-06-01 | |
| P1433 | published in | Journal of Hepatology | Q15724402 |
| P1476 | title | S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. | |
| P478 | volume | 30 |
| Q43588115 | 5'-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. |
| Q40571158 | 5'-methylthioadenosine modulates the inflammatory response to endotoxin in mice and in rat hepatocytes. |
| Q35962702 | A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study |
| Q36029791 | A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. |
| Q37091511 | A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis |
| Q35201613 | Aberrant hepatic methionine metabolism and gene methylation in the pathogenesis and treatment of alcoholic steatohepatitis |
| Q36752271 | Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis |
| Q46890423 | Addressing liver fibrosis with liposomes targeted to hepatic stellate cells |
| Q36578908 | Adipose tissue-liver axis in alcoholic liver disease |
| Q75253670 | Advances in alcoholic liver disease |
| Q35163801 | Advances in alcoholic liver disease |
| Q35580451 | Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease |
| Q27027418 | Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment |
| Q30939889 | Alcoholic hepatitis: pathophysiological data and therapeutic perspectives |
| Q88350010 | Alcoholic hepatitis: should we combine old drugs for better results? |
| Q34866009 | Alcoholic liver disease patients treated with S-adenosyl-L-methionine: an in-depth look at liver morphologic data comparing pre and post treatment liver biopsies |
| Q51764048 | Alcoholic liver disease. |
| Q92864037 | Alcoholic liver disease: A current molecular and clinical perspective |
| Q33870250 | Alcoholic liver disease: new insights in pathogenesis lead to new treatments |
| Q27690220 | Alcoholic liver disease: pathogenesis and new therapeutic targets |
| Q34473986 | Alcoholic liver injury: pathogenesis and therapy in 2001. |
| Q36750275 | Alcoholic steatohepatitis: management and prognosis |
| Q33419494 | Alterations in the glutathione metabolism could be implicated in the ischemia-induced small intestinal cell damage in horses |
| Q92990038 | Alterations of Methionine Metabolism as Potential Targets for the Prevention and Therapy of Hepatocellular Carcinoma |
| Q24244334 | Anabolic-androgenic steroids for alcoholic liver disease |
| Q24250225 | Anabolic-androgenic steroids for alcoholic liver disease |
| Q31097531 | Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. |
| Q33840604 | Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q85212590 | Antioxidants for liver disease |
| Q45268831 | Antioxidants in the treatment of chronic liver diseases: why is the efficacy evidence so weak in humans? |
| Q37681083 | Betulinic acid prevents alcohol-induced liver damage by improving the antioxidant system in mice |
| Q44628800 | Binding of Acetaldehyde to a Glutathione Metabolite: Mass Spectrometric Characterization of an Acetaldehyde‐Cysteinylglycine Conjugate |
| Q37043515 | Bioconjugation of oligonucleotides for treating liver fibrosis |
| Q43197147 | Challenge for doctors and policy makers |
| Q37640582 | Challenges in the diagnosis and management of autoimmune hepatitis |
| Q34408850 | Chronic liver inflammation: clinical implications beyond alcoholic liver disease |
| Q36206702 | Clinical implications of oxidative stress and antioxidant therapy. |
| Q34524372 | Cocarcinogenic effects of alcohol in hepatocarcinogenesis |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q38222882 | Current and prospective pharmacotherapy for autoimmune hepatitis |
| Q36655119 | Current concepts and controversies in the treatment of alcoholic hepatitis |
| Q35001014 | Developing strategies for liver fibrosis treatment |
| Q50574552 | Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with HCV infection. |
| Q28076505 | Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions |
| Q26799149 | Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1 |
| Q38920951 | Dietary supplementation in patients with alcoholic liver disease: a review on current evidence |
| Q31034873 | Dietary supplements |
| Q36339606 | Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease |
| Q90412564 | Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review |
| Q33263605 | Effect of resveratrol on alcohol-induced mortality and liver lesions in mice |
| Q43561630 | Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17beta-estradiol glucuronide-induced cholestasis |
| Q34449441 | Efficacy of the dietary supplement S-adenosyl-L-methionine |
| Q36478124 | Emerging therapies for liver fibrosis |
| Q40593096 | Exogenous nucleosides modulate the expression of rat liver extracellular matrix genes in single cultures of primary hepatocytes and a liver stellate cell line and in their co-culture |
| Q38783748 | Expansion of liver cancer stem cells during aging in methionine adenosyltransferase 1A-deficient mice |
| Q40412861 | Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages. |
| Q37386702 | Focus on: Alcohol and the liver |
| Q34774388 | Folate deficiency, methionine metabolism, and alcoholic liver disease |
| Q37078455 | Folate, alcohol, and liver disease |
| Q46641860 | From alcohol toxicity to treatment |
| Q36359677 | Gene expression patterns in the progression of canine copper-associated chronic hepatitis |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q42834672 | Hepatoprotective effects of antioxidants in chronic hepatitis C. |
| Q33699983 | Impaired terminal differentiation of pulmonary macrophages in a Guinea pig model of chronic ethanol ingestion |
| Q36895048 | Inflammation in alcoholic liver disease |
| Q43574315 | Inhibition of liver methionine adenosyltransferase gene expression by 3-methylcolanthrene: protective effect of S-adenosylmethionine. |
| Q36588200 | Interactions of cytokines, S-Adenosylmethionine, and S-Adenosylhomocysteine in alcohol-induced liver disease and immune suppression |
| Q36372382 | Interactions of ethanol and folate deficiency in development of alcoholic liver disease in the micropig. |
| Q38127461 | Intrahepatic cholestasis in common chronic liver diseases. |
| Q37229858 | KASL clinical practice guidelines: management of alcoholic liver disease |
| Q42266403 | Lipid peroxide levels and antioxidant status in alcoholic liver disease |
| Q36561560 | Management of alcoholic hepatitis: Current concepts |
| Q34597743 | Management strategies in alcoholic liver disease |
| Q45891738 | May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients? |
| Q33792440 | Mechanism for prevention of alcohol-induced liver injury by dietary methyl donors |
| Q35885731 | Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation |
| Q36588213 | Methionine adenosyltransferase and S-adenosylmethionine in alcoholic liver disease. |
| Q93184502 | Methionine adenosyltransferases in liver cancer |
| Q89389038 | Methionine adenosyltransferases in liver health and diseases |
| Q34635551 | Methionine synthase. a possible prime site of the ethanolic lesion in liver |
| Q24243006 | Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases |
| Q24244017 | Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases |
| Q90575012 | Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease |
| Q36572087 | Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases |
| Q38595071 | Molecular basis of alcoholic fatty liver disease: From incidence to treatment |
| Q36524368 | NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis |
| Q35628128 | New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments |
| Q39155727 | New paradigms in management of alcoholic hepatitis: a review |
| Q37733072 | Nitric oxide and redox regulation in the liver: part II. Redox biology in pathologic hepatocytes and implications for intervention |
| Q46705829 | Non-invasive monitoring of oxidant stress in alcoholic liver disease |
| Q26992163 | Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine |
| Q36506081 | Nutrition in alcoholic liver disease |
| Q37060098 | Obesity, inflammation, and the potential application of pharmaconutrition |
| Q38006957 | Oxidative stress and benefits of antioxidant agents in acute and chronic hepatitis |
| Q35816465 | Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence |
| Q98613138 | Oxidative stress in alcohol-related liver disease |
| Q35033336 | Oxidative stress in viral and alcoholic hepatitis |
| Q35607638 | Pathogenesis and management of alcoholic hepatitis. |
| Q36316956 | Pathophysiological basis for antioxidant therapy in chronic liver disease |
| Q38736327 | Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis. |
| Q37617944 | Pharmacotherapy of acute alcoholic hepatitis in clinical practice |
| Q38681092 | Pharmacotherapy of alcoholic liver disease in clinical practice |
| Q87739240 | Prednisolone plus S-adenosil-L-methionine in severe alcoholic hepatitis |
| Q30248578 | Promising therapies for treatment of nonalcoholic steatohepatitis |
| Q24236315 | Propylthiouracil for alcoholic liver disease |
| Q24245565 | Propylthiouracil for alcoholic liver disease |
| Q34339711 | Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis |
| Q35684499 | Proteomic analysis of human hepatoma cells expressing methionine adenosyltransferase I/III: Characterization of DDX3X as a target of S-adenosylmethionine |
| Q35872557 | Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease |
| Q62727088 | Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma |
| Q35944548 | Relationships between nutrition, alcohol use, and liver disease. |
| Q35206697 | Review article: Nutritional therapy in alcoholic liver disease |
| Q38175465 | Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis |
| Q35714125 | Review article: current management of alcoholic liver disease |
| Q36804166 | Role of S-adenosyl-L-methionine in liver health and injury |
| Q78001335 | Role of S-adenosyl-L-methionine in the treatment of liver diseases |
| Q73301376 | Role of S-adenosylmethionine in hyperhomocysteinemia and in the treatment of alcoholic liver disease |
| Q34774377 | Role of abnormal methionine metabolism in alcoholic liver injury |
| Q34774396 | S-Adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease |
| Q33890173 | S-Adenosylmethionine |
| Q38691239 | S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research |
| Q40300400 | S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro |
| Q77335023 | S-Adenosylmethionine modulates inducible nitric oxide synthase gene expression in rat liver and isolated hepatocytes |
| Q42061625 | S-Adenosylmethionine regulates connexins sub-types expressed by hepatocytes. |
| Q34774382 | S-Adenosylmethionine revisited: its essential role in the regulation of liver function |
| Q24188041 | S-adenosyl-L-methionine for alcoholic liver diseases |
| Q24246175 | S-adenosyl-L-methionine for alcoholic liver diseases |
| Q30759150 | S-adenosyl-L-methionine for alcoholic liver diseases. |
| Q24188235 | S-adenosyl-L-methionine for people with alcoholic liver disease |
| Q35182116 | S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis |
| Q35860276 | S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. |
| Q46496815 | S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes |
| Q28476040 | S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse |
| Q40512960 | S-adenosylhomocysteine sensitizes to TNF-alpha hepatotoxicity in mice and liver cells: a possible etiological factor in alcoholic liver disease |
| Q40649351 | S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes |
| Q26829356 | S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility |
| Q44967758 | S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl-x(S). |
| Q43875821 | S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. |
| Q46081358 | S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet |
| Q42480530 | S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter |
| Q34306534 | S-adenosylmethionine in liver health, injury, and cancer |
| Q39851067 | S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model |
| Q36691639 | S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation |
| Q38080431 | S-adenosylmethionine metabolism and liver disease. |
| Q28577149 | S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver |
| Q34597732 | S-adenosylmethionine stabilizes cystathionine beta-synthase and modulates redox capacity |
| Q26992208 | SAMe and HuR in liver physiology: usefulness of stem cells in hepatic differentiation research |
| Q41115685 | Selection and Characteristics of Fermented Salted Seafood (jeotgal)-Originated Strains with Excellent S-adenosyl-L-methionine (SAM) Production and Probiotics Efficacy |
| Q41852579 | Selection and characterization of Cheonggukjang (fast fermented soybean paste)-originated bacterial strains with a high level of S-adenosyl-L-methionine production and probiotics efficacy |
| Q36818022 | Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis |
| Q53592062 | Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. |
| Q28396388 | Sustained proliferation in cancer: Mechanisms and novel therapeutic targets |
| Q42522358 | Synergistic protection by S-adenosylmethionine with vitamins C and E on liver injury induced by thioacetamide in rats |
| Q35911123 | Targeted treatments for cirrhosis |
| Q38902371 | Targeting Hepatic Fibrosis in Autoimmune Hepatitis. |
| Q89281668 | Targeting Nrf-2 is a promising intervention approach for the prevention of ethanol-induced liver disease |
| Q37883929 | Targeting collagen expression in alcoholic liver disease |
| Q35928255 | The induction of growth arrest DNA damage-inducible gene 45 beta in human hepatoma cell lines by S-adenosylmethionine |
| Q35068022 | The management of alcoholic liver disease |
| Q37223251 | The methyl donor S-adenosylmethionine prevents liver hypoxia and dysregulation of mitochondrial bioenergetic function in a rat model of alcohol-induced fatty liver disease |
| Q36918881 | The role of nutritional therapy in alcoholic liver disease. |
| Q37709683 | The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet |
| Q34554574 | The use of selected nutrition supplements and complementary and alternative medicine in liver disease |
| Q38073028 | Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies |
| Q34619396 | Treatment of alcoholic hepatitis |
| Q82688643 | Treatment of alcoholic liver disease |
| Q35207505 | Treatment of decompensated alcoholic liver disease |
| Q47146711 | Tumor-suppressive effect of S-adenosylmethionine supplementation in a murine model of inflammation-mediated hepatocarcinogenesis is dependent on treatment longevity |
| Q44471247 | Utilization of hepatoprotectants within the National Health Insurance in Taiwan |
| Q26996316 | Vitamin-dependent methionine metabolism and alcoholic liver disease |
| Q79520430 | [Epigenetic changes and liver carcinogenesis] |
| Q85855129 | [Liver fibrogenesis: physiopathology] |
| Q77784964 | [New therapeutic strategies in liver fibrosis: pathogenic basis] |
| Q44430575 | l-Cysteine administration prevents liver fibrosis by suppressing hepatic stellate cell proliferation and activation |
Search more.